Publications

Summary of Publication 2022

March 28, 2022

Publications from Oct 1, 2021 to Sep 30, 2022

  1. Angsuwatcharakon P, Puthanakit T, Bunjoungmanee P, Anugulruengkitt S, Srimuan P, Kowitdamrong E, Savangsindh P, Sophonphan J, Tantawichien T, Tangsathapornpong A. High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy. Vaccine. 2021 Oct 8;39(42):6206-6209. doi: 10.1016/j.vaccine.2021.08.079.
  2. Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P. Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection. J Infect Dis. 2021 Oct 28;224(8):1410-1421. doi: 10.1093/infdis/jiab094.
  3. Thet D, Siritientong T, Sangarlangkarn A, Lwin HMS, Phonphithak S, Apornpong T, Avihingsanon A. Deterioration of Nutritional Status and Its Negative Association with Depression Among Older HIV-Infected Asian Population: A Four-Year Longitudinal Study. AIDS Res Hum Retroviruses. 2021 Oct 14. doi: 10.1089/AID.2021.0087. Online ahead of print.
  4. Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V, Paitoonpong L, Suwanpimolkul G, Torvorapanit P, Pradit R, Sophonphan J, Putcharoen O. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac J Allergy Immunol. 2021 Oct 31. doi: 10.12932/AP-250721-1197. 
  5. Hiransuthikul A, Chutinet A, Sophonphan J, Ubolyam S, Ruxrungtham K, Avihingsanon A. Incidence and Risk Factors of Ischemic Stroke and Transient Ischemic Attack Among People Living with HIV: A Longitudinal Cohort Study. AIDS Res Hum Retroviruses. 2021 Nov 17. doi: 10.1089/AID.2021.0046.
  6. Singkham N, Avihingsanon A, Brundage RC, Birnbaum AK, Thammajaruk N, Ruxrungtham K, Bunupuradah T, Kiertiburanakul S, Chetchotisakd P, Punyawudho B; LASA study team. Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients. Expert Rev Clin Pharmacol. 2021 Nov 26:1-10. doi: 10.1080/17512433.2022.2000858.
  7. Han WM, Law MG, Choi JY, Ditangco R, Kumarasamy N, Chaiwarith R, Ly PS, Khusuwan S, Merati TP, Do CD, Yunihastuti E, Azwa I, Lee MP, Pham TN, Chan YJ, Kiertiburanakul S, Ng OT, Tanuma J, Pujari S, Zhang F, Gani Y, Mave V, Ross J, Avihingsanon A; TREAT Asia HIV Observational Database of IeDEA Asia-Pacific. Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. HIV Med. 2021 Nov 23. doi: 10.1111/hiv.13211.
  8. Kawang K, Naoudom U, Kowitdamrong E, Kerr SJ, Ruxrungtham K, Nilaratanakul V. Sensitivity and specificity of anti-double-stranded RNA immunofluorescence for universal detection of viral infection in respiratory specimens. Heliyon. 2021 Nov 25;7(12):e08471. doi: 10.1016/j.heliyon.2021.e08471.
  9. Sudjaritruk T, Bunupuradah T, Aurpibul L, Kanjanavanit S, Chotecharoentanan T, Sricharoen N, Ounchanum P, Suntarattiwong P, Pornpaisalsakul K, Puthanakit T; CAL-D Study Group. Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial. Clin Infect Dis. 2021 Nov 2;73(9):1555-1564. doi: 10.1093/cid/ciab547.
  10. Kueakulpattana N, Wannigama DL, Luk-In S, Hongsing P, Hurst C, Badavath VN, Jenjaroenpun P, Wongsurawat T, Teeratakulpisan N, Kerr SJ, Abe S, Phattharapornjaroen P, Shein AMS, Saethang T, Chantaravisoot N, Amarasiri M, Higgins PG, Chatsuwan T. Multidrug-resistant Neisseria gonorrhoeae infection in heterosexual men with reduced susceptibility to ceftriaxone, first report in Thailand. Sci Rep. 2021 Nov 4;11(1):21659. doi: 10.1038/s41598-021-00675-y.
  11. Gatechompol S, Sophonphan J, Kerr SJ, Ubolyam S, Avihingsanon A, van Leth F, Cobelens F. Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV. Int J Tuberc Lung Dis. 2021 Nov 1;25(11):933-938. doi: 10.5588/ijtld.21.0300.
  12. Supanan R, Han WM, Harnpariphan W, Ueaphongsukkit T, Ubolyam S, Sophonphan J, Tangkijvanich P, Thanprasertsuk S, Avihingsanon A; HIV-NAT HCV Study Team. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand. J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):465-469. doi: 10.1097/QAI.0000000000002801.
  13. Douglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, Fitch KV, Kileel EM, Aberg JA, Currier J, Sponseller CA, Melbourne K, Avihingsanon A, Bustorff F, Estrada V, Ruxrungtham K, Saumoy M, Navar AM, Hoffmann U, Ribaudo HJ, Grinspoon S. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021 Dec 6;73(11):2009-2022. doi: 10.1093/cid/ciab552.
  14. Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793.
  15. Han WM, Law MG, Egger M, Wools-Kaloustian K, Moore R, McGowan C, Kumarasamy N, Desmonde S, Edmonds A, Davies MA, Yiannoutsos C, Althoff KN, Cortes CP, Mohamed TJ, Jaquet A, Anastos K, Euvrard J, Castelnuovo B, Salters K, Coelho LE, Ekouevi DK, Eley B, Diero L, Zaniewski E, Ford N, Sohn AH, Kariminia A; IeDEA collaboration. Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. Lancet HIV. 2021 Dec;8(12):e766-e775. doi: 10.1016/S2352-3018(21)00265-4.
  16. Srisomwat C, Yakoh A, Avihingsanon A, Chuaypen N, Tangkijvanich P, Vilaivan T, Chailapakul O. An alternative label-free DNA sensor based on the alternating-current electroluminescent device for simultaneous detection of human immunodeficiency virus and hepatitis C co-infection. Biosens Bioelectron. 2022 Jan 15;196:113719. doi: 10.1016/j.bios.2021.113719.
  17. Romo ML, Patel RC, Edwards JK, Humphrey JM, Musick BS, Bernard C, Maina MW, Brazier E, Castelnuovo B, Penner J, Wyka K, Cardoso SW, Ly PS, Kunzekwenyika C, Cortés CP, Panczak R, Kelvin EA, Wools-Kaloustian KK, Nash D; International epidemiology Databases to Evaluate AIDS (IeDEA). Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity: An Observational Study. Ann Intern Med. 2022 Jan;175(1):84-94. doi: 10.7326/M21-3037. 
  18. Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022 Jan 10:S2468-1253(21)00397-6. doi: 10.1016/S2468-1253(21)00397-6.
  19. Thitipatarakorn S, Chinbunchorn T, Peelay J, Seekaew P, Amatavete S, Sangsai M, Pankam T, Avihingsanon A, Avery M, Phanuphak P, Ramautarsing R, Phanuphak N. Prevalence and the associated factors of hepatitis B and hepatitis C viral infections among HIV-positive individuals in same-day antiretroviral therapy initiation program in Bangkok, Thailand. BMC Public Health. 2022 Jan 20;22(1):144. doi: 10.1186/s12889-021-12429-6.
  20. Srisomwat C, Yakoh A, Avihingsanon A, Chuaypen N, Tangkijvanich P, Vilaivan T, Chailapakul O. An alternative label-free DNA sensor based on the alternating-current electroluminescent device for simultaneous detection of human immunodeficiency virus and hepatitis C co-infection. Biosens Bioelectron. 2022 Jan 15;196:113719. doi: 10.1016/j.bios.2021.113719. 
  21. Chuaypen N, Khlaiphuengsin A, Prasoppokakorn T, Susantitaphong P, Prasithsirikul W, Avihingsanon A, Tangkijvanich P, Praditpornsilpa K. Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia. BMC Infect Dis. 2022 Jan 22;22(1):79. doi: 10.1186/s12879-022-07074-2.
  22. Singkham N, Avihingsanon A, Brundage RC, Birnbaum AK, Thammajaruk N, Ruxrungtham K, Bunupuradah T, Kiertiburanakul S, Chetchotisakd P, Punyawudho B; LASA study team. Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients. Expert Rev Clin Pharmacol. 2022 Jan;15(1):99-108. doi: 10.1080/17512433.2022.2000858.
  23. Anugulruengkitt S, Angsuwatcharakon P, Puthanakit T, Bunjoungmanee P, Srimuan P, Kowitdamrong E, Sawangsinth P, Sophonphan J, Tantawichien T, Tangsathapornpong A. Seroprevalence of mumps among children and adolescents in Thailand, 2020. Vaccine. 2022 Feb 16;40(8):1061-1064. doi: 10.1016/j.vaccine.2022.01.019. 
  24. Hiransuthikul A, Chutinet A, Sophonphan J, Ubolyam S, Ruxrungtham K, Avihingsanon A. Short Communication: Incidence and Risk Factors of Ischemic Stroke and Transient Ischemic Attack Among People Living with HIV: A Longitudinal Cohort Study. AIDS Res Hum Retroviruses. 2022 Feb;38(2):131-134. doi: 10.1089/AID.2021.0046. 
  25. Sapwarobol S, Tangkijvanich P, Avihingsanon A, Kongruttanachok N, Jantarapakde J, Jiamjarasrangsi W. Neck circumference as a screening measure for identifying NAFLD among a group of academic employees in Bangkok, Thailand. PLoS One. 2022 Feb 17;17(2):e0263826. doi: 10.1371/journal.pone.0263826. 
  26. Rupasinghe D, Choi JY, Kumarasamy N, Pujari S, Sun LP, Merati TP, Lee MP, Kinh NV, Kiertiburanakul S, Do CD, Avihingsanon A, Ross J, Jiamsakul A; on behalf of IeDEA Asia-Pacific. Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific. HIV Med. 2022 Feb 25. doi: 10.1111/hiv.13280. 
  27. Tumkosit M, Han WM, Tankittiwat K, Chattranukulchai P, Siwamogsatham S, Apornpong T, Ureaphongsukkit T, Kerr SJ, Boonyaratavej S, Avihingsanon A; HIV-NAT 006/207 study team. Higher epicardial fat in older adults living with HIV with viral suppression and relationship with liver steatosis, coronary calcium and cardiometabolic risks. AIDS. 2022 Feb 24. doi: 10.1097/QAD.0000000000003204.
  28. Boettiger DC, An VT, Kumarasamy N, Azwa I, Sudjaritruk T, Truong KH, Avihingsanon A, Ross J, Kariminia A; International Epidemiology Databases to Evaluate AIDS – Asia-Pacific. Recent trends in adult and pediatric antiretroviral therapy monitoring and failure. J Acquir Immune Defic Syndr. 2022 Feb 3. doi: 10.1097/QAI.0000000000002931.
  29. Han WM, Law MG, Choi JY, Ditangco R, Kumarasamy N, Chaiwarith R, Ly PS, Khusuwan S, Merati TP, Do CD, Yunihastuti E, Azwa I, Lee MP, Pham TN, Chan YJ, Kiertiburanakul S, Ng OT, Tanuma J, Pujari S, Zhang F, Gani Y, Mave V, Ross J, Avihingsanon A; TREAT Asia HIV Observational Database of IeDEA Asia-Pacific. Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. HIV Med. 2022 Mar;23(3):274-286. doi: 10.1111/hiv.13211. 
  30. Kim JH, Jiamsakul A, Kiertiburanakul S, Huy BV, Khusuwan S, Kumarasamy N, Ng OT, Ly PS, Lee MP, Chan YJ, Gani YM, Azwa I, Avihingsanon A, Merati TP, Pujari S, Chaiwarith R, Zhang F, Tanuma J, Do CD, Ditangco R, Yunihastuti E, Ross J, Choi JY; IeDEA Asia-Pacific. Patterns and prognosis of holding regimens for people living with HIV in Asian countries. PLoS One. 2022 Mar 30;17(3):e0264157. doi: 10.1371/journal.pone.0264157. 
  31. Harnpariphan W, Han WM, Supanan R, Ubolyam S, Sophonphan J, Ueaphongsukkit T, Gatechompol S, Tangkijvanich P, Thanprasertsuk S, Khwairakpam G, Ruxrungtham K, Phanuphak P, Matthews GV, Avihingsanon A . High proportion of blood-borne and sexually transmitted infections among people deprived of liberty in a central male prison in Thailand: a cross-sectional study 2018-2019. AIDS Res Hum Retroviruses. 2022 Mar 9. doi: 10.1089/AID.2021.0134. Online ahead of print.
  32. Nanthapisal S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, Sodsai P, Himananto O, Sophonphan J, Suchartlikitwong P, Hiransuthikul N, Angkasekwinai P, Tangsathapornpong A, Hirankarn N; study team. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. Vaccine. 2022 Apr 20;40(18):2551-2560. doi: 10.1016/j.vaccine.2022.03.036.
  33. Sangarlangkarn A, Apornpong T, Woodard J, Jordan A, Avihingsanon A. Correlation Between Polypharmacy and Frailty Among Thai Older Persons Living with HIV. AIDS Res Hum Retroviruses. 2022 Mar 24. doi: 10.1089/AID.2021.0214. Online ahead of print.
  34. Trabwongwitaya P, Songtaweesin WN, Paiboon N, Wongharn P, Moonwong J, Phiphatkhunarnon P, Sowaprux T, Sophonphan J, Hansasuta P, Puthanakit T. Preference and ability to perform blood-versus oral-fluid-based HIV self-testing in adolescents and young adults in Bangkok. Int J STD AIDS. 2022 Mar 8:9564624221076955. doi: 10.1177/09564624221076955.
  35. Ohata PJ, Gatechompol S, Lwin HMS, Han WM, WichiansanT, Songtaweesin W, Ross J, Kerr SJ, Avihingsanon A and Phanuphak P on behalf of the Bangkok Symposium Team. Conference proceedings from virtual 24th Bangkok International Symposium on HIV Medicine. Published in Future Virology. www.futuremedicine.com/doi/10.2217/fvl-2022-0023
  36. Solomon SS, Wagner-Car doso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):307-317. doi: 10.1016/S2468-1253(21)00397-6.
  37. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. 
  38. Suwanpimolkul G, Gatechompol S, Kawkitinarong K, Ueaphongsukkit T, Sophonphan J, Siriyakorn N, Jirajariyavej S, Khusuwan S, Panarat P, Wannalerdsakun S, Saetiew N, Chayangsu S, Wiwatrojanagul S, Noopetch P, Danpornprasert P, Mekviwattanawong S, Fujitnirun C, Lertpiriyasuwat C, Han WM, Kerr SJ, Ruxrungtham K, Avihingsanon A; the HIV-TB study team. Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy. J Int AIDS Soc. 2022 Apr;25(4):e25900. doi: 10.1002/jia2.25900.
  39. Jantarabenjakul W, Sodsai P, Chantasrisawad N, Jitsatja A, Ninwattana S, Thippamom N, Ruenjaiman V, Tan CW, Pradit R, Sophonphan J, Wacharapluesadee S, Wang LF, Puthanakit T, Hirankarn N, Putcharoen O. Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. Vaccines (Basel). 2022 Apr 19;10(5):639. doi: 10.3390/vaccines10050639.
  40. Gatechompol S, Sophonphan J, Ubolyam S, Avihingsanon A, van Leth F, Cobelens F, Kerr SJ. Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model. BMC Infect Dis. 2022 Apr 7;22(1):346. doi: 10.1186/s12879-022-07332-3.
  41. Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigators. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542.
  42. Harnpariphan W, Han WM, Supanun R, Ubolyam S, Sophonphan J, Ueaphongsukkit T, Gatechompol S, Tangkijvanich P, Thanprasertsuk S, Khwairakpam G, Ruxrungthan K, Phanuphak P, Matthews GV, Avihingsanon A. High Proportion of Blood-Borne and Sexually Transmitted Infections Among People Deprived of Liberty in a Central Male Prison in Thailand: A Cross-Sectional Study 2018-2019. AIDS Res Hum Retroviruses. 2022 May;38(5):370-377. doi: 10.1089/AID.2021.0134.
  43. Nantanee R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, Himananto O, Theerawit T, Sophonphan J, Tovichayathamrong P, Manothummetha K, Laohasereekul T, Hiransuthikul N, Hirankarn N, Puthanakit T; Study Team. Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac. Vaccine. 2022 May 26;40(24):3320-3329. doi: 10.1016/j.vaccine.2022.04.067. 
  44. Boettiger DC, An VT, Kumarasamy N, Azwa I, Sudjaritruk T, Truong KH, Avihingsanon A, Ross J, Kariminia A; International Epidemiology Databases to Evaluate AIDS—Asia-Pacific. Recent Trends in Adult and Pediatric Antiretroviral Therapy Monitoring and Failure. J Acquir Immune Defic Syndr. 2022 Jun 1;90(2):193-200. doi: 10.1097/QAI.0000000000002931.
  45. Nantanee R, Jantarabenjakul W, Jaru-Ampornpan P, Sodsai P, Himananto O, Athipunjapong J, Sophonphan J, Nanthapisal S, Hirankarn N, Puthanakit T; Study Team. A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. Vaccines (Basel). 2022 Jun 8;10(6):914. doi: 10.3390/vaccines10060914.
  46. Khuon D, Rupasinghe D, Saphonn V, Kwong TS, Widhani A, Chaiwarith R, Ly PS, Do CD, Avihingsanon A, Khusuwan S, Merati TP, Van Nguyen K, Kumarasamy N, Chan YJ, Azwa I, Ng OT, Kiertiburanakul S, Tanuma J, Pujari S, Ditangco R, Zhang F, Choi JY, Gani Y, Sangle S, Ross J, Gorbach PM, Jiamsakul A; IeDEA Asia-Pacific. BMI as a predictor of high fasting blood glucose among people living with HIV in the Asia-Pacific region. HIV Med. 2022 Jun 24. doi: 10.1111/hiv.13351.
  47. Chuaypen N, Siripongsakun S, Hiranrat P, Tanpowpong N, Avihingsanon A, Tangkijvanich P. Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants. PLoS One. 2022 Jun 13;17(6):e0269641. doi: 10.1371/journal.pone.0269641.
  48. Ross JL, Jiamsakul A, Avihingsanon A, Lee MP, Ditangco R, Choi JY, Rajasuriar R, Gatechompol S, Chan I, Melgar MIE, Kim JH, Chong ML, Sohn AH, Law M; Substance use, Stigma, Depression and Disability (S2D2) study group of IeDEA Asia-Pacific. Prevalence and Risks of Depression and Substance Use Among Adults Living with HIV in the Asia-Pacific Region. AIDS Behav. 2022 Jun 6:1-16. doi: 10.1007/s10461-022-03714-5. 
  49. Maimongkol P, Yonwises W, Anugulruengkitt S, Sophonphan J, Treyaprasert W, Wacharachaisurapol N. Therapeutic drug monitoring of meropenem and pharmacokinetic-pharmacodynamic target assessment in critically ill pediatric patients from a prospective observational study. Int J Infect Dis. 2022 Jul;120:96-102. doi: 10.1016/j.ijid.2022.04.052. 
  50. Theerasuwipakorn N, Rungpradubvong V, Chattranukulchai P, Siwamogsatham S, Satitthummanid S, Apornpong T, Ohata PJ, Han WM, Kerr SJ, Songmuang SB, Avihingsanon A and HIV-NAT 006 and 207 study teams. Higher prevalence of QTc Interval Prolongation among Virologically Suppressed Older People Living with HIV. AIDS. (In Press)
  51. Kumpuangdee S, Roomruangwong C, Sophonphan J, Ohata PJ, Suwanpimolkul G. Prevalence of depression and anxiety in pulmonary tuberculosis patients and its association with unsuccessful treatment outcome: A prospective cohort. Indian Journal of Tuberculosis (in Press) 

A5288 study

  1. Erlandson KM, Fitch KV, McCallum SA, Ribaudo HJ, Overton ET, Zanni MV, Bloomfield GS, Brown TT, Fichtenbaum CJ, Bares S, Aberg JA, Douglas PS, Fulda ES, Santana-Bagur JL, Castro JG, Moran LE, Mave V, Supparatpinyo K, Ponatshego PL, Schechter M, Grinspoon SK. Geographical Differences in the Self-Reported Functional Impairment of People with HIV and Associations with Cardiometabolic Risk. Clin Infect Dis.2022 Feb 15;ciac098. doi: 10.1093/cid/ciac098. Online ahead of print.
  2. Lobby SE, Kantor A, Burdo TH, Currier JS, Fichtenbaum CJ, Overton ET, Aberg JA, Malvestutto CD, Bloomfield GS, Erlandson KM, Cespedes M, Kallas EG, Masia M, Thornton AC, Smith MD, Flynn JM, Kileel EM, Fulda E, Fitch KV, Lu MT, Douglas PS, Grinspoon SK, Ribaudo HJ, Zanni MV. Factors Associatedd with Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People with HIV on Antiretroviral Therapy. Clin Infect Dis. 2022 Mar 2;ciac166. doi: 10.1093/cid/ciac166. Online ahead of print.
  3. Kolossvary M, deFilippi C, Lu MT, Zanni MV, Fulda ES, Foldyna B, Ribaudo H, Mayrhofer T, Collier AC, Bloomfield GS, Fichtenbaum C, Overton ET, Aberg JA, Currier J, Fitch KV, Douglas PS, Grinspoon SK. Proteomic Signature of Subclinical Coronary Artery Disease in People with HIV: Analysis of the REPRIEVE Mechanistic Substudy. J Infect Dis. 2022 May 10;jiac196. doi: 10.1093/infdis/jiac196. Online ahead of print.
  4. Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Faesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Schalkwyk MV, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B for the A5288 Study team. Third-line antiretroviral therapy including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR) is well tolerated and achieves durable virologic suppression over 144 weeks in resource limited settings: ACTG A5288 strategy trial. JIAS. (In Press)

A5349 study

  1. Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 25;71(8):285-289. doi: 10.15585/mmwr.mm7108a1. PMID: 35202353.
  2. Phillips PPJ, Kurbatova EV, Dorman SE. Four-Month Rifapentine Regimens for Tuberculosis. Reply. N Engl J Med. 2022 Mar 17;386(11):1095-1096. doi: 10.1056/NEJMc2114483. PMID: 35294823.